Company intelligence / Profile preview

UTokyo Innovation Platform

Tokyo, Tokyo, Japan

Ownership: Private
Development stage: Other

Overview

UTokyo Innovation Platform is an active investment and incubation firm wholly owned by the University of Tokyo, supporting and growing deep tech startups in life sciences, healthcare, biotech, and related sectors, with portfolio companies advancing regenerative medicine, genome engineering, nucleic acid-based therapies, and drug discovery.

Therapeutic areas: OncologyCardiovascularOtherRare Diseases
Modalities: Induced pluripotent stem cell derived therapySmall moleculeNucleic acid-based drugs (Antisense oligonucleotide, Small interfering RNA, mRNA-based drugs, Gene therapy)Peptides
Industry: Investors

Partnerships

Academic partners (Eight major Japanese universities)Corporate partners (Ajinomoto, ENEOS, etc. for 1stRound program)

Beyond the preview

Go deeper on UTokyo Innovation Platform.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UTokyo Innovation Platform.

Explore the full profile